AAVantgarde to Showcase Innovative Findings at ESGCT 2024
AAVantgarde's Major Presence at ESGCT Annual Meeting
AAVantgarde Bio, an innovative clinical-stage biotechnology company, is set to make a significant impact at the upcoming European Society of Gene & Cell Therapy (ESGCT) annual meeting. This year, the conference will take place in a vibrant European city and run from October 22 to 25. AAVantgarde’s participation includes three important oral presentations that highlight its advancements in gene therapy.
Breakthrough Work in Gene Therapy
As a company dedicated to pioneering treatments, AAVantgarde Bio has developed two proprietary Adeno-Associated Viral (AAV) vector platforms which are promising for large gene delivery. The firm seeks to address the challenges associated with cargo capacity limitations of traditional AAV vectors. AAVantgarde is currently validating its technologies in two inherited retinal diseases, focusing particularly on Usher syndrome type 1B, which is already undergoing clinical trials, and Stargardt disease, which is progressing toward clinical studies.
Presentation Highlights
At the ESGCT event, AAVantgarde will present vital preclinical data derived from their Stargardt program, detailing crucial insights into the process development, analytics, and manufacturing of its dual vectors. Such advancements ensure that clinical supplies for its ambitious therapeutic programs are achievable. A renowned figure in the field, Professor Alberto Auricchio, TIGEM Scientific Director and Scientific Founder of AAVantgarde, will be presenting on the accelerated development of AAV-based gene therapies.
Oral Presentation Details
On Tuesday, October 22, 2024, AAVantgarde’s presentations are scheduled as follows:
- 14:00-16:30 CEST - Session: ExpEditing AAV Gene Therapy, Room: Plenary Hall, Abstract Number: INV01
- 17:00-19:30 CEST - Session: Safety and Expression of Intein-Based Dual AAV8.ABCA4 in Non-Human Primate Retina, Room: Meeting Room 2, Abstract Number: OR017
Furthermore, on Friday, October 25, 2024, another presentation will occur:
- 11:00-13:00 CEST - Session: Production of Dual AAV Vectors for Delivery of Large Genes, Room: Plenary Hall, Abstract Number: INV73
Company Overview
AAVantgarde Bio stands out in the biotechnology sector due to its innovative approach to gene therapy. The company’s focus on large gene delivery through its unique AAV vector platforms showcases its commitment to addressing unmet needs in gene therapy. Currently, AAVantgarde is at the forefront of research for ophthalmological conditions, ensuring that developments are not just theoretical but are indeed actionable and beneficial to patients.
Contact Information
For more inquiries regarding AAVantgarde's work and upcoming presentations, individuals can reach out to:
Magda Blanco
Head of Corporate Development
AAVantgarde
Email: info@avvantgarde.com
Frequently Asked Questions
What is AAVantgarde?
AAVantgarde is a clinical-stage biotechnology company specializing in gene therapy using proprietary AAV vector platforms.
What conferences will AAVantgarde present at?
AAVantgarde is scheduled to present at the ESGCT Annual Meeting in October 2024.
What topics will be covered in the presentations?
The presentations will focus on advancements in AAV gene therapy, safety, preclinical data, and dual vector production.
Who is the scientific founder of AAVantgarde?
Professor Alberto Auricchio is the Scientific Founder and TIGEM Scientific Director of AAVantgarde.
How can I contact AAVantgarde?
You can contact AAVantgarde via email at info@avvantgarde.com for any inquiries.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.